Mirtazapine
- Generic Name
- Mirtazapine
- Brand Names
- Remeron
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N3
- CAS Number
- 85650-52-8
- Unique Ingredient Identifier
- A051Q2099Q
- Background
Mirtazapine is a tetracyclic piperazino-azepine antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder. The effects of this drug may be observed as early as 1 week after beginning therapy.
In addition to its beneficial effects in depression, mirtazapine has been reported to be efficacious in the off-label management of various other conditions. It may improve the symptoms of neurological disorders, reverse weight loss caused by medical conditions, improve sleep, and prevent nausea and vomiting after surgery.
- Indication
This drug is indicated for the treatment of major depressive disorder and its associated symptoms.
Mirtazapine has been used off-label for a variety of conditions including panic disorder, generalized anxiety disorder, dysthymia, tension headaches, hot flushes, post-traumatic stress disorder (PTSD), sleep disorders, substance abuse disorders, and sexual disorders, among others.
- Associated Conditions
- Cancer Pain, Depression, Fibromyalgia, Generalized Anxiety Disorder, Hot Flashes, Insomnia, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Persistent Depressive Disorder (Dysthymia), Post Operative Nausea and Vomiting (PONV), Poststroke depression, Sleep disorders and disturbances, Substance Abuse Disorders, Tension Headache
PET Neuroimaging of [11C]Mirtazapine
- Conditions
- Mental DisordersMood DisordersAffective DisordersDepressive Disorders
- First Posted Date
- 2006-02-08
- Last Posted Date
- 2007-04-19
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 24
- Registration Number
- NCT00288782
- Locations
- 🇩🇰
Center for Psychiatric Research, Psychiatric Hospital of Aarhus University, Risskov, Denmark
Mirtazapine for Treating Cocaine Dependent Individuals Who Also Suffer From Depression
- First Posted Date
- 2005-11-07
- Last Posted Date
- 2017-10-25
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 86
- Registration Number
- NCT00249444
- Locations
- 🇺🇸
Research Foundation for Mental Hygiene, Inc., New York, New York, United States
Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study
- Conditions
- Bipolar Disorder
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2005-09-15
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 60
- Registration Number
- NCT00177567
- Locations
- 🇺🇸
University of Pittsubrgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2020-12-14
- Lead Sponsor
- University of Erlangen-Nürnberg Medical School
- Target Recruit Count
- 80
- Registration Number
- NCT00150839
- Locations
- 🇩🇪
Department of Psychiatry and Psychotherapy, University Erlangen-Nuremberg, Erlangen, Bavaria, Germany
New Pharmacological Treatment for Obstructive Sleep Apnea
- Conditions
- Obstructive Sleep Apnea
- First Posted Date
- 2005-04-18
- Last Posted Date
- 2009-01-21
- Lead Sponsor
- US Department of Veterans Affairs
- Registration Number
- NCT00108498
- Locations
- 🇺🇸
Malcom Randall VAMC, Gainesville, Florida, United States
Treatment of Adolescent Suicide Attempters (TASA)
- Conditions
- Suicide, AttemptedDepression
- First Posted Date
- 2004-03-26
- Last Posted Date
- 2020-06-22
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 120
- Registration Number
- NCT00080158
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Columbia University at the New York State Psychiatric Institute, New York, New York, United States
🇺🇸New York University Child Study Center, New York, New York, United States
Sequenced Treatment Alternatives to Relieve Depression (STAR*D)
- Conditions
- Depression
- First Posted Date
- 2001-07-23
- Last Posted Date
- 2009-09-25
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 4000
- Registration Number
- NCT00021528
- Locations
- 🇺🇸
Harbor UCLA Family Health Care Center, Harbor City, California, United States
🇺🇸UCLA General Outpatient Psychiatry Clinic, Los Angeles, California, United States
🇺🇸UCLA Internal Medicine Clinic, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.